[
    [
        {
            "time": "",
            "original_text": "中国证监会行政行政处罚决定书（姚朝梨） 金融监管处罚",
            "features": {
                "keywords": [
                    "证监会",
                    "行政处罚",
                    "姚朝梨",
                    "金融监管"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中国证监会行政行政处罚决定书（姚朝梨） 金融监管处罚",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "云南白药子公司人员涉嫌行贿 主业增速疲软“炒股”暴赚26亿 关联方问题",
            "features": {
                "keywords": [
                    "云南白药",
                    "子公司",
                    "涉嫌行贿",
                    "主业增速疲软",
                    "炒股",
                    "暴赚26亿",
                    "关联方问题"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "云南白药子公司人员涉嫌行贿 主业增速疲软“炒股”暴赚26亿 关联方问题",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "3月以来，医药生物板块成保险机构调研新宠",
            "features": {
                "keywords": [
                    "3月以来",
                    "医药生物",
                    "保险机构",
                    "调研",
                    "新宠"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3月以来，医药生物板块成保险机构调研新宠",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]